T0	Participants 72 96	advanced gastric cancer.
T1	Participants 258 282	gastric cancer patients.
T2	Participants 349 376	63 gastric cancer patients.
T3	Participants 417 651	Group F, 16 cases who received a single administration of 5-fluorouracil (5-FU); Group C, 15 cases who received a single administration of cis-diamminedichloroplatinum (CDDP; cisplatin); Group FC, 16 cases who received both 5-FU+CDDP;
T4	Participants 656 715	a Control group, 16 cases who did not receive chemotherapy.
T5	Participants 1555 1569	gastric cancer